BioCardia, Inc. (BCDA) Financial Ratios
30 years of historical data (1995–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.3·High7.2
P/FCF
N/A
—
5yr avg: N/A
30Y Low21.8·High37.9
P/B Ratio
↑
3.57
↓-68% vs avg
5yr avg: 11.21
30Y Low0.2·High109.6
ROE
↓
-949.3%
↑-133% vs avg
5yr avg: -406.7%
30Y Low-477%·High119%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low1.3·High27.0
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BCDA Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
BioCardia, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5M | $6M | $14M | $111M | $98M | $105M | $62M | $138M | $269M | $325M | $4M |
| Enterprise Value | $4M | $5M | $14M | $105M | $87M | $84M | $58M | $133M | $256M | $304M | $-3672516 |
| P/E Ratio → | -0.38 | — | — | — | — | — | — | — | — | — | 13.96 |
| P/S Ratio | 86.47 | 103.14 | 29.48 | 82.15 | 97.02 | 724.36 | 87.77 | 221.06 | 561.65 | 565.08 | 8.70 |
| P/B Ratio | 3.57 | 7.15 | — | 22.71 | 9.49 | 5.48 | 26.29 | 36.43 | 24.18 | 15.81 | 0.32 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | 21.82 |
| P/OCF | — | — | — | — | — | — | — | — | — | — | 13.58 |
P/E links to full P/E history page with 30-year chart
BCDA EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 78.65 | 29.93 | 77.91 | 86.18 | 580.96 | 81.51 | 212.48 | 535.16 | 528.01 | -7.10 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | -10.03 |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | -11.51 |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | -17.83 |
BCDA Profitability
Margins and return-on-capital ratios measuring operating efficiency
BioCardia, Inc. earns an operating margin of -13794.8%. Operating margins have compressed from -880.3% to -13794.8% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -949.3% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -7463.8% | -7463.8% | -1519.7% | -553.4% | 36.9% | 97.2% | 49.6% | 17.3% | -44.1% | -29.5% | -324.0% |
| Operating Margin | -13794.8% | -13794.8% | -2441.1% | -880.3% | -1244.3% | -10709.7% | -2001.8% | -2256.3% | -2589.8% | -1320.8% | 61.7% |
| Net Profit Margin | -13700.0% | -13700.0% | -2425.8% | -880.7% | -1243.4% | -10347.6% | -2071.7% | -2237.9% | -2569.5% | -1789.9% | 62.3% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -949.3% | -949.3% | -703.6% | -156.0% | -85.4% | -139.3% | -477.4% | -187.5% | -77.6% | -59.9% | 2.3% |
| ROA | -236.8% | -236.8% | -181.1% | -93.3% | -64.5% | -96.5% | -208.7% | -140.2% | -69.1% | -57.3% | 2.3% |
| ROIC | — | — | — | — | — | — | — | — | — | -231.6% | 3.6% |
| ROCE | -2046.3% | -2046.3% | -416.8% | -130.7% | -81.0% | -135.9% | -376.8% | -187.1% | -77.9% | -44.1% | 2.3% |
BCDA Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $2M exceeds total debt of $951000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.14 | 1.14 | — | 0.33 | 0.18 | 0.03 | 0.48 | — | — | — | 0.41 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | 15.50 |
| Net Debt / Equity | — | -1.70 | — | -1.17 | -1.06 | -1.08 | -1.87 | -1.41 | -1.14 | -1.04 | -0.59 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | -22.32 |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | -39.65 |
| Interest Coverage | — | — | — | -1983.50 | — | -5176.33 | -126.90 | — | — | -4.38 | — |
Net cash position: cash ($2M) exceeds total debt ($951000)
BCDA Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.13x means BioCardia, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 2.19x to 1.13x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.13 | 1.13 | 0.40 | 2.19 | 3.63 | 5.33 | 1.59 | 2.44 | 5.71 | 15.18 | 1387.60 |
| Quick Ratio | 1.13 | 1.13 | 0.40 | 2.19 | 3.63 | 5.33 | 1.59 | 2.39 | 5.63 | 15.08 | 1311.70 |
| Cash Ratio | 1.02 | 1.02 | 0.31 | 2.05 | 3.47 | 5.04 | 1.40 | 2.10 | 5.44 | 14.79 | 1384.00 |
| Asset Turnover | — | 0.02 | 0.16 | 0.14 | 0.06 | 0.01 | 0.09 | 0.10 | 0.04 | 0.03 | 0.04 |
| Inventory Turnover | 89.50 | — | — | — | — | — | 89.50 | 3.67 | 3.61 | 5.53 | 1.40 |
| Days Sales Outstanding | — | — | 48.21 | 54.26 | 52.86 | 584.00 | 75.57 | 160.02 | 72.39 | 46.89 | — |
BCDA Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
BioCardia, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | 7.2% |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | 4.6% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $3M | $1M | $1M | $1M | $674579 | $376289 | $284279 | $282671 | $61987 | $11558 |
Peer Comparison
Compare BCDA with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BCDAYou | $5M | -0.4 | — | — | -7463.8% | -13794.8% | -949.3% | — | — |
 MCRB | $74M | 12.1 | — | 86.0 | -423.8% | -11910.1% | 19.6% | -90.3% | — |
 ANIK | $203M | -19.9 | — | 46.5 | 56.6% | -9.8% | -7.3% | -7.1% | — |
 NVCR | $2B | -13.8 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 ADMA | $2B | 14.1 | 10.1 | 73.1 | 57.4% | 37.5% | 35.6% | 36.0% | 0.4 |
 VCEL | $2B | 109.8 | 79.8 | 72.3 | 74.4% | 4.0% | 5.1% | 2.5% | 4.4 |
 FATE | $280M | -2.1 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 MDXG | $548M | 11.5 | 5.1 | 7.5 | 82.6% | 15.3% | 21.6% | 42.3% | 0.3 |
 RGEN | $7B | 147.0 | 52.4 | 75.9 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 CYTK | $9B | -11.4 | — | — | 88.5% | -695.4% | — | -305.3% | — |
 BSX | $84B | 29.2 | 25.3 | 23.0 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
See BCDA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs BCDA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare BCDA vs MCRB
Side-by-side business, growth, and profitability comparison vs Seres Therapeutics, Inc..
Start ComparisonBCDA — Frequently Asked Questions
Quick answers to the most common questions about buying BCDA stock.
What is BioCardia, Inc.'s P/E ratio?
BioCardia, Inc.'s current P/E ratio is -0.4x. The historical average is 13.8x.
What is BioCardia, Inc.'s ROE?
BioCardia, Inc.'s return on equity (ROE) is -949.3%. The historical average is -88.0%.
Is BCDA stock overvalued?
Based on historical data, BioCardia, Inc. is trading at a P/E of -0.4x. Compare with industry peers and growth rates for a complete picture.
What are BioCardia, Inc.'s profit margins?
BioCardia, Inc. has -7463.8% gross margin and -13794.8% operating margin.